Viking Therapeutics's latest marketcap:
As of 08/13/2025, Viking Therapeutics's market capitalization has reached $4.64 B. According to our data, Viking Therapeutics is the 3624th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.64 B |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -171,547,000 |
| Shares Out | 112.44 M |
| EPS (ttm) | -1.54 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/23/2025 |
Viking Therapeutics's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/13/2025 | $4.64 B | -4.99% | 3624 |
| 12/31/2024 | $4.48 B | 140.89% | 3253 |
| 12/29/2023 | $1.86 B | 158.22% | 5879 |
| 12/30/2022 | $720.9 M | 100.31% | 10064 |
| 12/31/2021 | $359.9 M | -12.37% | 15411 |
| 12/31/2020 | $410.7 M | -29.14% | 12714 |
| 12/31/2019 | $579.6 M | 6.02% | 9311 |
| 12/31/2018 | $546.7 M | 372.52% | 8676 |
| 12/29/2017 | $115.7 M | 382.08% | 17229 |
| 12/30/2016 | $24 M | -27.27% | 22562 |
Company Profile
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, the company focuses on groundbreaking treatments to address unmet medical needs.
Key Drug Candidates
- VK2809: An orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently in Phase IIb clinical trials for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
- VK5211: An orally available non-steroidal selective androgen receptor modulator in Phase II clinical trials for patients recovering from non-elective hip fracture surgery.
- VK0612: An orally available Phase IIb-ready drug candidate targeting type 2 diabetes.
- VK2735: A novel dual agonist of the glucagon-like peptide, currently in Phase 1 SAD/MAD clinical trials.
- VK0214: An orally available TRß agonist under development for X-linked adrenoleukodystrophy.
With a strong pipeline of promising therapies, Viking Therapeutics is committed to advancing cutting-edge treatments for patients worldwide.
Frequently Asked Questions
-
What is Viking Therapeutics's (VKTX) current market cap?As of 08/13/2025, Viking Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $4.64 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Viking Therapeutics (VKTX) rank globally by market cap?Viking Therapeutics global market capitalization ranking is approximately 3624 as of 08/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.